Conference item : Poster
Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
- Publication status:
- Published
- Peer review status:
- Reviewed (other)
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 158.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjy222.848
Authors
- Publisher:
- Oxford University Press
- Host title:
- Journal of Crohns and Colitis
- Journal:
- Journal of Crohns and Colitus More from this journal
- Volume:
- 13
- Issue:
- S1
- Pages:
- S483-S484
- Publication date:
- 2019-01-25
- Event title:
- 14th Congress of ECCO
- Event location:
- Copenhagen, Denmark
- Event website:
- https://www.ecco-ibd.eu/ecco19.html
- Event start date:
- 2019-03-06
- Event end date:
- 2019-03-09
- DOI:
- EISSN:
-
1873-9946
- ISSN:
-
1876-4479
- Language:
-
English
- Subtype:
-
Poster
- Pubs id:
-
pubs:985157
- UUID:
-
uuid:291b83e9-77ec-4b08-9e30-6eed00cc42a1
- Local pid:
-
pubs:985157
- Source identifiers:
-
985157
- Deposit date:
-
2019-03-28
- ARK identifier:
Terms of use
- Copyright holder:
- Card et al
- Copyright date:
- 2019
- Rights statement:
- © The Author(s) 2019. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved.
- Notes:
- This paper was presented at the 14th Congress of European Crohn's and Colitis Organisation (ECCO 2019), 6-9 March 2019, Copenhagen, Denmark.
If you are the owner of this record, you can report an update to it here: Report update to this record